Genomic alterations and gene expression in primary diffuse large B‐cell lymphomas of immune‐privileged sites: the importance of apoptosis and immunomodulatory pathways

Abstract excerpt

Primary diffuse large B-cell lymphomas of different immune-privileged sites (IP-DLBCLs) share many clinical and biological features, such as a relatively poor prognosis, preferential dissemination to other immune-privileged sites, and deletion of the HLA region, which suggests that IP-DLBCL represents a separate entity. To further investigate the nature of IP-DLBCL, we investigated site-specific genomic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CNS Lymphoma Diagnosis and Treatment
• Share to Immune Cell Function and Interaction
• Share to Lymphoma Diagnosis and Treatment